53. Motegrity

shire
(Shire)

Active ingredient: prucalopride
Disease: chronic idiopathic constipation
Peak sales estimate: n/a
Approved: Dec. 17
Company: Shire

The scoop: Synergy Pharmaceuticals wasn’t able to seriously challenge Allergan’s Linzess in the market with Trulance, but now Shire is going to give it a try. It’ll be wielding Motegrity, a constipation treatment that works by stimulating muscle movement in the colon. Regulators OK’d the drug after an advisory panel endorsed it unanimously, voting 10-0 in favor of an approval and signaling its satisfaction with Shire data showing the drug didn’t come with the same cardiovascular safety risks as other products in its class of 5-HT4 treatments. The green light was also a win for Takeda, which will soon swallow Shire as part of a $62 billion buyout, and it should bring a little peace of mind to some Takeda investors that opposed the deal. — Carly Helfand

 

53. Motegrity

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.